ADDED
- 1534248 - 2023 2023-05-31 2024-10-31 0001534248 FY false The weighted average share price is based on the Company s ordinary share valuation as at the grant date.
Expected life for the periods presented was determined according to the simplified method since, at the date of grant, the Company did not have enough history to make an estimate.
This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award.
The simplified method is applicable to service conditions and for performance conditions that are probable of achievement.
If meeting the performance condition is not probable, the Company will use the awards contractual term if the service period is implied, or the simplified method, if the service period is explicitly stated.
Expected volatility is based on historical volatility over the most recent period commensurate with the expected term of the option.
As the Company has a short trading history for its ordinary shares, when the Company's trading period is shorter than the expected term, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company s industry that the Company considers to be comparable to its own business over a period equivalent to the option s expected term.
The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S.
Treasury securities with maturities appropriate for the expected term of employee share option awards.
(Exact name of registrant as specified in its charter) Israel 81-3676773 (State or other jurisdiction of (I.R.S.
REMOVED
As of March 24, 2022, the registrant had 228,090,300 ordinary shares outstanding (which is equivalent to 11,404,515 American Depositary Shares, each representing twenty ordinary shares, outstanding).
Exhibits and Financial Statement Schedules 81 Item 16 Form 10-K Summary 82 2 PART I In this Annual Report on Form 10-K, unless the context otherwise requires: references to Chemomab Therapeutics Ltd.
, Chemomab, the Company, us, we and our refer to Chemomab Therapeutics Ltd.
risks related to previous announced combination with Chemomab including with respect to the change of our business prospects, new product candidates, and clinical development plans following such combination; risks related to a failure to complete the previous announced combination with Chemomab, including our ability to support our operation with limited cash runway.
Based on these findings, Chemomab is actively advancing CM-101 into Phase 2 clinical studies directed toward two distinct clinical indications including patients with liver, skin, and/or lung fibrosis.
The study is actively recruiting patients in Europe and Israel and is being expanded by adding additional dosing arms as well as an open label extension.
The Company also plans to extend the trial by adding new territories with significant recruitment potential.
In addition, we are planning to initiate a Phase 2 clinical trial in SSc in the second half of 2022.
The trial in SSc, a rare autoimmune rheumatic disease characterized by fibrosis in the skin and the lung, will focus on establishing biological and clinical proof of concept in this patient population following treatment with CM-101.
Although our primary focus relates to these two rare indications, an additional Phase 2 clinical study is currently enrolling patients with liver fibrosis derived due to non-alcoholic steatohepatitis, or NASH.